NV
Novo Nordisk
NVO · NYSE
$46.63 -1.86% (-$0.89)
1M -1.40%
Market Cap 1.36T kr
P/E Ratio 11.65x
Div. Yield 3.78%
ROE 59.09%
Bulios Fair Price
$59.91
28.5% upside
Current Price
$46.63
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NVO is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
61 /100
Fair P/E 11.65x
EV/EBITDA 8.03x
P/S 4.12x
Growth
75 /100
Growing EPS growth 23.52%
Rev. growth 20.43%
FCF growth 23.26%
Profitability
96 /100
Strong Gross margin 80.65%
Net margin 35.35%
Op. margin 43.13%
Quality
92 /100
Excellent ROIC 29.73%
ROE 59.09%
ROA 19.57%
Debt
81 /100
Low Debt/Equity 0.63x
Current ratio 0.87x
Int. coverage 30.76x
Stability
70 /100
Stable Beta 0.35x
Rev. volatility 12.92%
EPS volatility 25.50%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NVO
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Maziar Mike Doustdar
Employees
68,794
Headquarters
Bagsvaerd
Upcoming events
04 NOV
Earnings
Upcoming earnings report